A Phase 3b Study to Investigate the Safety and Efficacy of Undiluted Intravenous Infusion of I.V.-Hepabig Inj. in Post-liver Transplant Patients
Latest Information Update: 01 Jul 2025
At a glance
- Drugs Lenvervimab (Primary)
- Indications Hepatitis B
- Focus Adverse reactions; Registrational
- Sponsors GC Biopharma
Most Recent Events
- 25 Jun 2025 Planned number of patients changed from 200 to 105.
- 25 Jun 2025 Planned End Date changed from 1 Sep 2025 to 30 Jun 2026.
- 25 Jun 2025 Planned primary completion date changed from 1 Dec 2024 to 30 Jun 2026.